AUTHORS
Ghada Araji, MD, Kriti Gera, MD2, Hana Qasim, Fellow3, Jamila Mammadova, MD, MA4, Daniela Carolina Carolina Bravo Solarte, MD5, Yanina Pasikhova6, Biwei Cao7, Jongphil Kim, PhD8, Michael D. Jain, MD, PhD9, Frederick L. Locke, MD10, Nima Ghalehsari, MD11, Sayeef Mirza, BS, MPH, MD12, Alaa Ali, MD13, Nancy Torres, MD14, Bijal Shah, MD, MS15, Eric Gaskill, PharmD16, Sameh Gaballa, MD17, Jennifer Logue, MD, BS, BA18, Joseph Pidala I, MD19, John Greene, MD20, Aliyah Baluch, MD21, Brahm Segal, MD22, Taiga Nishihori, MD23, Rawan Faramand, MD24, Farhad Khimani, MD25, Nelli Bejanyan, MD26, Jeff Hosry, MD27, Olga Klinkova, MD28, Aleksandr Lazaryan, MD MPH PhD29
AFFILIATIONS
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
20 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
21 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
22 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
23 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
24 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
25 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
26 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
27 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
28 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
29 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
ABSTRACT
Background: Chimeric antigen receptor T-cell therapy (CAR T) and allogeneic hematopoietic cell transplantation (alloHCT) are potentially curative for relapsed/refractory B-cell malignancies, but each can cause prolonged immune dysfunction. The cumulative infectious and immunologic consequences of alloHCT after prior CAR T remain poorly defined. We characterized infectious complications, infection density (ID), immune reconstitution, and survival during the first year after alloHCT in CAR T-exposed patients.
Methods: We retrospectively studied 43 adults with B-NHL (n=27) or B-ALL (n=16) who underwent alloHCT after CAR T-cell therapy at our center between 2015 and 2025. Infectious events within 1 year after alloHCT were identified by chart review and classified as bacterial, viral, fungal, or unknown etiology. ID was calculated as events per 100 patient-days at risk. Laboratory-confirmed and clinically diagnosed bacterial, viral, and fungal infections were included. Fever of unknown etiology requiring hospitalization and empiric antimicrobial therapy was included in the primary analysis. Colonization, asymptomatic bacteriuria, untreated low-level CMV/EBV viremia, asymptomatic respiratory viral positivity or chronic shedding, and blood-culture contaminants were excluded. Immune reconstitution was assessed using serial lymphocyte subsets by flow cytometry and serum IgG levels. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Non-relapse mortality (NRM) and infection-related mortality (IRM) were estimated using competing-risk methodology.
Results: Median age at alloHCT was 58 years (IQR, 48-66), and 67.4% were male. Prior CAR T products were axi-cel (47%), brexu-cel (44%), and tisa-cel (9%). Median interval from CAR T to alloHCT was 9.3 months. Conditioning was myeloablative, reduced-intensity, and nonmyeloablative in 32.6%, 34.9%, and 32.6%, respectively; 74.4% received post-transplant cyclophosphamide (PTCy)-based graft-versus-host-disease (GVHD) prophylaxis.
Overall, 167 infectious events occurred in 42/43 patients (97.7%) over 12,015 patient-days, yielding an overall ID of 1.39 per 100 patient-days (95% CI, 1.19–1.62). Events were bacterial in 40.7%, viral in 27.5%, fungal in 7.8%, and unknown in 24.0%. Most morbidity was early: ID was 6.11 during days 0-30 and declined to 1.42, 0.89, and 0.52 during days 31-90, 91-180, and 181-365, respectively. Bacterial infections were concentrated within the first 100 days (ID 1.06) and were less frequent thereafter (ID 0.32). ID was 1.52 and 1.16 per 100 patient-days in patients with B-NHL and B-ALL, respectively. Overall, 57.5% of events were CTCAE grade ≥3, 78.4% required systemic antimicrobial therapy, and 3 patients (7.0%) experienced infection-related death. In a sensitivity analysis restricted to PTCy-based recipients and to microbiologically or clinically confirmed infections — mirroring the historical benchmark (Khimani et al, TCT 2021) — ID was 1.15 per 100 patient-days (95% CI, 0.94–1.40) versus 0.50 in the PTCy-based alloHCT benchmark, corresponding to an incidence rate ratio (IRR) of 2.3 (95% CI, 1.83–2.90). With median follow-up of 33.9 months, 2-year OS, PFS, NRM, and IRM were 72.4%, 60.4%, 20.1%, and 10.4%, respectively.
The first immune-reconstitution assessment occurred at a median of 87 days post-HCT, with median CD4+, CD8+, NK, and CD19+ counts of 167/uL, 158/uL, 139/uL, and <25/uL, respectively. Serial monitoring showed gradual T-cell recovery, with median CD4+ counts increasing from 60/uL at day +30 to 308/uL at day +365, but persistent B-cell impairment, with median CD19+ counts of 25/uL through day +90, 37/uL at day +180, and 73/uL at day +365. IgG levels remained low: first median IgG was 345 mg/dL at median day 67, 61% had initial IgG <400 mg/dL, and median IgG was 436, 385, 513, and 440 mg/dL at days +30, +90, +180, and +365.
Conclusion: AlloHCT following CAR T-cell therapy was associated with a substantially increased infectious burden relative to historical alloHCT benchmarks, severe infections, delayed CD4+ recovery, persistent B-cell depletion, and prolonged hypogammaglobulinemia. These findings support evaluation of risk-adapted antimicrobial prophylaxis, enhanced surveillance, and immune-directed supportive care to reduce infection-related morbidity and mortality in this vulnerable population, while ongoing comparative studies seek to define the independent contribution of prior CAR T-cell therapy.
DISCLOSURES
Ghada Araji, MD: No relevant conflicts of interest to declare.